InvestorsHub Logo
Followers 59
Posts 18522
Boards Moderated 0
Alias Born 11/29/2006

Re: None

Wednesday, 05/09/2018 8:27:13 PM

Wednesday, May 09, 2018 8:27:13 PM

Post# of 1615
MA 2
2 hours ago
yahoo msg

Seems pretty clear that the "Executive Vice President for Quality Assurance", whose name is redacted from FRE's answer and counterclaim is Mark Silverberg. Of the comparatively few discovery requests that FRE has served in the litigation to date, they subpoenaed Silverberg to sit for deposition on June 12 in Sidley Austin's Chicago Offices (PW doesn't have a chicago office but instead of picking a random location, they are using FRE's investigation counsel's offices). Seems interesting to me that Silverberg is not represented by Cravath, and has his own counsel (likely paid for by AKRX). Another kind of interesting thing is that Silverberg's insider trading was alleged by plaintiffs in a derivative suit against ARKX in 2015 as evidence of demand futility.

Imo this doesn't show much other than what we already know - FRE is putting a lot of stock in its azithromycin fraudulent data argument. Inaction by the FDA looks better and better for AKRX as each day goes by imo, and the recent FDA approvals for ARKX don't look good for FRE's materiality showing.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.